SUMMARY -Thiopurine S-methyltransferase (TPMT) is an enzyme that converts thiopurine drugs into inactive metabolites. Over 20 variant TPMT-encoding alleles, which cause reduced enzymatic activity, have been discovered so far. Our aim was to investigate the frequencies of variant alleles, i.e. genotypes in inflammatory bowel disease (IBD) patients and healthy individuals and to compare these frequencies with selected world populations. The most common variant alleles TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C were analyzed with polymerase chain reactionbased assays and allele-specific polymerase chain reaction-based assays in 685 participants including 459 IBD patients and 226 healthy volunteers. Study results revealed 434/459 (94.55%) IBD patients and 213/226 (94.25%) healthy subjects to be homozygous for the wild-type allele (TPMT*1/*1). TPMT*1/*2 and TPMT *1/*3C genotypes were found in 4/459 (0.87%) and 7/459 (1.53%) IBD patients, respectively; in healthy volunteers they were not found. TPMT*1/*3A genotype was found in 14/459 (3.05%) IBD patients and 13/226 (5.75%) healthy subjects. Variant genotypes were statistically significantly more common in Crohn's disease subgroup than in ulcerative colitis subgroup. The prevalence of variant genotypes was 23/338 (6.80%) in Crohn's disease subgroup as compared with 2/121 (1.65%) in ulcerative colitis subgroup (χ 2 =4.59; p=0.032). In conclusion, the most frequently occurring nonfunctional TPMT allele in Croatian population is TPMT*3A. The overall frequency of mutant alleles in our population is statistically nonsignificantly lower when compared with other populations of Caucasian origin. The Crohn's disease group had more mutant alleles than the ulcerative colitis group.
Introduction
Thiopurine drugs (azathioprine, 6-thioguanine and 6-mercaptopurine) are extensively used as steroidsparing drugs in autoimmune disorders, hematologic malignancies, inflammatory bowel diseases (IBD) and in organ transplantation 1 . Although very useful, they have a narrow therapeutic index (the ratio between therapeutic efficacy and toxicity).
In humans, thiopurines are metabolized via three competing pathways: (a) oxidation by xanthine oxidase (XO) (product is an inactive metabolite 6-thiouric acid); (b) phosphorybosyl transfer by hypoxanthine guanine phosphoribosyltransferase (HGRPT) (products are 6-thioguanine nucleotides); and (c) methylation by thiopurine-methyltransferase (TPMT) (product is 6-methylmercaptopurine) 2 . The balance between Agata Ladić et al.
TPMT polymorphisms in an IBD patient cohort these three pathways determines the amount of final product and henceforth the therapeutic efficacy/toxicity of thiopurine drugs. During the last three decades, TPMT has been extensively studied. It is a cytosolic enzyme encoded by TPMT gene [3] [4] [5] . Up to now, more than 20 allelic variants of the gene have been found. The majority of them contain a single nucleotide polymorphism leading to amino acid substitution. The most frequent allelic variants are denoted TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C 6 . Each of these variants codes TPMT protein that undergoes rapid proteolysis and results in TPMT deficiency 7 . Caucasians show a trimodal gene distribution: 89% of subjects are homozygous for wild type gene (denoted TPMT*1/*1); 6%-11% of subjects are heterozygous (one wild-type allele and one variant allele); and 0.33% of subjects are homozygous for some variant allele [8] [9] . This finding has clinical implications: "wildtype" patients get full dose of the drug; "heterozygous" patients get reduced dose; and "variant homozygous" patients do not get the drug in order to avoid possible toxicity.
The frequency distribution of variant alleles varies among countries, in particular among continents. Out of the aforementioned variant alleles, TPMT*3C is found mostly in African and Asian inhabitants, TPMT*3A in European and Northern American inhabitants, and TPMT*2 in Latin American inhabitants.
A few reports on Slavic populations have revealed differences in the frequency of variant alleles among Slavic populations [10] [11] [12] [13] [14] [15] . This is the first study on TPMT polymorphisms in a Croatian population of IBD patients. In addition, the study compared variant allele frequencies between healthy Croatian subjects and IBD cohort in order to determine whether there is an association between TPMT variants and IBD; and between Croatian population and selected world populations to determine interethnic differences.
Patients, Materials and Methods

Study population
A total of 685 Croatian subjects participated in the study, including 459 IBD patients (338 with Crohn's disease, (CD) group and 121 with ulcerative colitis, (UC) group) and 226 healthy adult volunteers (control group). The participants with IBD were recruited among in-and outpatients admitted to the Zagreb University Hospital Center and Osijek University Hospital Center. Control subjects were selected among hospital staff and other Zagreb citizens appointed for routine check-up.
Ethical approval for the study was obtained from the Ethics Committees of the Zagreb University Hospital Center and School of Medicine, University of Zagreb. All procedures were performed in accordance with ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration from 1975, as revised in 2008. A written informed consent was obtained from all subjects.
Blood samples were collected in Vacutainer tubes using EDTA as anticoagulant.
TPMT genotyping
Genomic DNA was extracted from peripheral lymphocytes using the salting out procedure 16 . Detection of the single nucleotide polymorphisms (SNPs) of TPMT was carried out using a validated Real-time PCR method, TaqMan® Drug Metabolism Genotyping Assay obtained from Applied Biosystems (Foster City, CA, USA); Assay ID: TPMT*2 (rs1800462), C_12091552_30; TPMT*3B (rs1800460), C_30634116_20; TPMT*3C (rs1142345), C_19567_20. The TaqMan® primer/probe set designed for each SNP allele was included in the kits.
Polymerase chain reactions (PCR) were performed in a 96-well microplate format in 15 µL reaction mixture containing TaqMan® universal PCR master mix and using amplification protocol of 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 92 °C for 15 s, then 60 °C for 1.5 min. The following allelic discrimination analysis was carried out using the 500 Real Time PCR Systems (Applied Biosystems, Foster City, CA, USA). TPMT genotyping analysis is included in external quality control schemes (DGKL, Germany).
The inflammatory bowel disease was defined according to the standard criteria 17, 18 .
Statistical analysis
Differences in TPMT genotype frequencies between the groups were analyzed using the χ 2 -test. In 
Results
A total of 685 Croatian participants were enrolled in the study, 459/685 (67.0%) of them IBD patients and 226/685 (33.0%) healthy volunteers. In IBD group, there were 338 patients with Crohn's disease and 121 patients with ulcerative colitis.
No significant deviations from the expected Hardy-Weinberg proportions were observed in either control group (p>0.999) or IBD group (p>0.999).
None of the participants was homozygous for any of the investigated variant allele.
In IBD group, 434/459 (94.55%) subjects were homozygous for the wild-type allele (TPMT*1/*1) versus 213/226 (94.25%) control subjects. Difference in the prevalence of homozygous wild-type alleles between the control and IBD groups was not statistically significant (χ 2 =0.03; p=0.870). TPMT*1/*2 genotype was found in 4/459 (0.87%) and TPMT*1/*3C in 7/459 (1.53%) IBD patients. Neither of these variants was found in control group. Differences for these two genotypes were not statistically significant (p=0.308 and p=0.102, respectively) ( Table 1) .
TPMT*1/*3A genotype was found in 14/459 (3.05%) IBD patients and 13/226 (5.75%) control subjects. Difference between IBD and control groups did not reach statistical significance (p=0.087).
Analysis of CD and UC subgroups yielded statistically significant differences; mutant genotypes were more common in CD subgroup (23/338, 6.80%) as compared with UC subgroup (2/121, 1.65%) (χ 2 =4.59; p=0.032) ( Table 2) . TPMT polymorphisms in an IBD patient cohort
Comparison of TPMT allelic frequency between Croatia and other countries
We were interested in the historical background of TPMT variants in different parts of the world and therefore compared our results with selected countries for which data were available (Table 3) .
TPMT*3A was the most prevalent variant allele in Croatia (27/ 
Discussion
Our results showed the most common variant allele in Croatian population to be TPMT*3A (1.97% of mutant alleles). This is in concordance with the previous result reported on Croatian population 35 , although with a smaller frequency. Some differences in the prevalence of TPMT alleles between Croats and neighboring countries (Slovenia), as well as other Caucasian populations could be discussed and explained considering genotyping methods that were applied. In earlier researches, PCR-RFLP methods were used, which were found to be less accurate than Real-time PCR methods that were applied in this and some other recently published investigations. The results for the Croatian and Slovenian samples do not differ for TPMT*2 variant allele, as the Real-time PCR was applied on both sides, but differ for other alleles where the methods were different 12 . Our data are in accordance with the data obtained for Serbian population 14 . Since our laboratory is taking part in the external quality control schemes (DGKL, Germany) for TPMT genotyping, we are rather confident for the data presented in this study. Another advantage of our study was a larger number of participants compared to other published data.
Another interesting and to us unexpected finding was that CD patients had a greater proportion of mutant alleles than UC patients. The frequency of variant alleles in the UC group was 1.65%, while in the CD group it was 6.80%. A limitation of this finding is that we had almost twice more participants in CD group than in UC group. We carried out this study in a tertiary referral center, where we had more patients with extensive Crohn's disease. This possibly presents a chance finding because of a selection bias. A similar Russian study found a statistically significant difference in the frequencies of carriers of variant alleles between the malignancy group and control group, with a greater frequency in the malignancy group 10 . Both these findings urge the question that mutant alleles somehow 'weaken' the genetic construction of a person, which could be a basis for new investigations.
Studies done so far speculated that TPMT*3C is the ancestral allele, originating from the northeastern Africa. This allele is present to some degree in all populations, but mostly in African and Asian. TPMT*3A and all other variant alleles were probably acquired over centuries through migrations and mixing of civilizations. Genetic analysis of modern Croatian population shows it to be a territory of an extraordinary genetic mixture 36 . However, there was no significant mixing of Croatians with African populations, which could be the reason why Croats exhibit mostly TPMT*3A as the most prevalent variant allele and not TPMT*3C, just as other Caucasian populations.
Conclusion
Our results confirm that TPMT*3A is the most prevalent allele in IBD population, as well as in general Croatian population. This is in concordance with other Caucasian populations. Variant alleles were more prevalent in CD than in UC patients, which could be the basis for new investigations.
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